Trial Profile
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Recombinant CMV gB Vaccine in Postpartum Women.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2017
Price :
$35
*
At a glance
- Drugs Cytomegalovirus glycoprotein vaccine (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 19 Sep 2011 Planned end date changed from 1 Feb 2010 to 1 Jan 2010 as reported by ClinicalTrials.gov.
- 19 May 2009 Actual patient number changed from 441 to 464 as reported by ClinicalTrials.gov.
- 19 May 2009 Planned end date changed from 1 Oct 2009 to 1 Feb 2010 as reported by ClinicalTrials.gov.